{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T11:51:05Z","timestamp":1782215465290,"version":"3.54.5"},"reference-count":86,"publisher":"Termedia Sp. z.o.o.","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pol J Pathol"],"abstract":"<jats:p>The purpose of this study is to explore the clinical and pathological characteristics as well as the molecular pathogenesis of patients with non-small cell lung cancer (NSCLC) transforming into small cell lung cancer (SCLC). &lt;br \/&gt;\nWe investigated 14 patients with advanced NSCLC that transformed into SCLC. Whole genome sequencing (WES) was applied to analyse 14 tumour specimens (including NSCLC and SCLC specimens from each patient) from 7 patients to detect genetic predictive factors for small-cell transformation. The clinicopatho\u00adlogical characteristics of these 14 patients were collected and analysed. In addition, a detailed literature review was conducted to identify similar cases of transforma\u00adtion from NSCLC to SCLC. &lt;br \/&gt;\nFourteen cases were included. The basic condition of patients who had undergone the transformation was found to be similar to those individuals without any trans\u00adformation. After SCLC transformation, the mutation spectrum changed: C&gt;T de\u00adcreased and C&gt;A increased. In comparison to the initial NSCLC, the copy number variants (CNV) burden in the transformed SCLC increased considerably in a subset of patients. Clonal evolution analysis revealed intriguing connections and notable differences between the genetic clones of the initial NSCLC and the transformed SCLC. It was found that the process of transformation took a longer time in fe\u00admales compared to males. Furthermore, it was observed that the transformation time for LADC was longer compared to squamous cell carcinoma (SCC). Addition\u00adally, the analysis revealed that after completion of the transformation, the OS time for males was found to be longer than that for females. &lt;br \/&gt;\nSecondary biopsy is a crucial step in assessing the genetic and histological alter\u00adations that occur after a patient develops resistance to their initial treatment. This procedure is vital not only for individuals who have been treated with tyrosine kinase inhibitors but also for those who have undergone chemotherapy or immuno\u00adtherapy. One interesting finding is that the mutation rate of p53 and RB1 in trans\u00adformed SCLC is lower compared to de novo SCLC. Specifically, there is a decrease in the C &gt; T mutation and an increase in the C &gt; A mutation following transforma\u00adtion. Moreover, the transformed SCLC appears to originate from the major clones of the initial NSCLC.<\/jats:p>","DOI":"10.5114\/pjp.2025.153971","type":"journal-article","created":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T09:21:34Z","timestamp":1758532894000},"page":"94-109","source":"Crossref","is-referenced-by-count":0,"title":["Clinicopathological and molecular features of non-small cell lung cancer that transform to small-cell lung cancer: Case reports and literature review"],"prefix":"10.5114","volume":"76","author":[{"given":"Qiqi","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulong","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3061","published-online":{"date-parts":[[2025,9,22]]},"reference":[{"key":"ref-1687997","doi-asserted-by":"crossref","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020; 70: 7-30.","DOI":"10.3322\/caac.21590"},{"key":"ref-1687998","doi-asserted-by":"crossref","unstructured":"Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010; 362: 2380-2388.","DOI":"10.1056\/NEJMoa0909530"},{"key":"ref-1687999","doi-asserted-by":"crossref","unstructured":"Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cispla\u00adtin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lan\u00adcet Oncol 2010; 11: 121-128.","DOI":"10.1016\/S1470-2045(09)70364-X"},{"key":"ref-1688000","doi-asserted-by":"crossref","unstructured":"Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastat\u00adic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013; 31: 3327-34.","DOI":"10.1200\/JCO.2012.44.2806"},{"key":"ref-1688001","doi-asserted-by":"crossref","unstructured":"Engelman JA, Janne PA. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 2008; 14: 2895- 2899.","DOI":"10.1158\/1078-0432.CCR-07-2248"},{"key":"ref-1688002","doi-asserted-by":"crossref","unstructured":"Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carbopla\u00adtin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947-957.","DOI":"10.1056\/NEJMoa0810699"},{"key":"ref-1688003","doi-asserted-by":"crossref","unstructured":"Farago AF, Piotrowska Z, Sequist LV. Unlocking the Mystery of Small-Cell Lung Cancer Transformations in EGFR Mutant Adenocarcinoma. J Clin Oncol 2017; 35: 2987-2988.","DOI":"10.1200\/JCO.2017.73.5696"},{"key":"ref-1688004","doi-asserted-by":"crossref","unstructured":"Oser MG, Niederst MJ, Sequist LV, Engelman JA. Transforma\u00adtion from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin. Lancet Oncol 2015; 16: e165-e172.","DOI":"10.1016\/S1470-2045(14)71180-5"},{"key":"ref-1688005","doi-asserted-by":"crossref","unstructured":"Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011; 3: 75ra26.","DOI":"10.1126\/scitranslmed.3002003"},{"key":"ref-1688006","doi-asserted-by":"crossref","unstructured":"Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med 2017; 377: 1919-1929.","DOI":"10.1056\/NEJMoa1709937"},{"key":"ref-1688007","doi-asserted-by":"crossref","unstructured":"Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med 2015; 373: 1627-1639.","DOI":"10.1056\/NEJMoa1507643"},{"key":"ref-1688008","doi-asserted-by":"crossref","unstructured":"Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. N Engl J Med 2018; 379: 2040-2051.","DOI":"10.1056\/NEJMoa1810865"},{"key":"ref-1688009","doi-asserted-by":"crossref","unstructured":"Shen Q, Qu J, Sheng L, Gao Q, Zhou J. Case Report: Transfor\u00admation From Non-Small Cell Lung Cancer to Small Cell Lung Cancer During Anti-PD-1 Therapy: A Report of Two Cases. Front Oncol 2021; 11: 619371.","DOI":"10.3389\/fonc.2021.619371"},{"key":"ref-1688010","doi-asserted-by":"crossref","unstructured":"Sehgal K, Varkaris A, Viray H, VanderLaan PA, Rangachari D, Costa DB. Small cell transformation of non-small cell lung cancer on immune checkpoint inhibitors: uncommon or un\u00adder-recognized? J Immunother Cancer 2020; 8: e000697.","DOI":"10.1136\/jitc-2020-000697"},{"key":"ref-1688011","doi-asserted-by":"crossref","unstructured":"Ahn S, Hwang SH, Han J, et al. Transformation to Small Cell Lung Cancer of Pulmonary Adenocarcinoma: Clinicopathologic Analysis of Six Cases. J Pathol Transl Med 2016; 50: 258-263.","DOI":"10.4132\/jptm.2016.04.19"},{"key":"ref-1688012","doi-asserted-by":"crossref","unstructured":"Oya Y, Yoshida T, Uemura T, Murakami Y, Inaba Y, Hida T. Serum ProGRP and NSE levels predicting small cell lung cancer transformation in a patient with ALK rearrangement-positive non-small cell lung cancer: A case report. Oncol Lett 2018; 16: 4219-4222.","DOI":"10.3892\/ol.2018.9158"},{"key":"ref-1688013","doi-asserted-by":"crossref","unstructured":"Ferrer L, Giaj Levra M, Brevet M, et al. A Brief Report of Transformation From NSCLC to SCLC: Molecular and Ther\u00adapeutic Characteristics. J Thorac Oncol 2019; 14: 130-134.","DOI":"10.1016\/j.jtho.2018.08.2028"},{"key":"ref-1688014","doi-asserted-by":"crossref","unstructured":"Iams WT, Beckermann KE, Almodovar K, et al. Small Cell Lung Cancer Transformation as a Mechanism of Resistance to PD-1 Therapy in KRAS-Mutant Lung Adenocarcinoma: A Re\u00adport of Two Cases. J Thorac Oncol 2019; 14: e45-e48.","DOI":"10.1016\/j.jtho.2018.11.031"},{"key":"ref-1688015","doi-asserted-by":"crossref","unstructured":"Bar J, Ofek E, Barshack I, et al. Transformation to small cell lung cancer as a mechanism of resistance to immunotherapy in non-small cell lung cancer. Lung Cancer 2019; 138: 109-115.","DOI":"10.1016\/j.lungcan.2019.09.025"},{"key":"ref-1688016","doi-asserted-by":"crossref","unstructured":"Okeya K, Kawagishi Y, Muranaka E, et al. Hyperprogressive Disease in Lung Cancer with Transformation of Adenocarcino\u00adma to Small-cell Carcinoma during Pembrolizumab Therapy. Intern Med 2019; 58: 3295-3298.","DOI":"10.2169\/internalmedicine.2892-19"},{"key":"ref-1688017","doi-asserted-by":"crossref","unstructured":"Abdallah N, Nagasaka M, Abdulfatah E, Shi D, Wozniak AJ, Sukari A. Non-small cell to small cell lung cancer on PD-1 inhibitors: two cases on potential histologic transformation. Lung Cancer (Auckl) 2018; 9: 85-90.","DOI":"10.2147\/LCTT.S173724"},{"key":"ref-1688018","doi-asserted-by":"crossref","unstructured":"Imakita T, Fujita K, Kanai O, et al. Small cell lung cancer transformation during immunotherapy with nivolumab: A case report. Respir Med Case Rep. 2017; 21: 52-55.","DOI":"10.1016\/j.rmcr.2017.03.019"},{"key":"ref-1688019","doi-asserted-by":"crossref","unstructured":"Takegawa N, Hayashi H, Iizuka N, Terashima T, Mio T. Trans\u00adformation of ALK rearrangement-positive adenocarcinoma to small-cell lung cancer in association with acquired resistance to alectinib. Ann Oncol 2016; 27: 953-955.","DOI":"10.1093\/annonc\/mdw032"},{"key":"ref-1688020","doi-asserted-by":"crossref","unstructured":"Fujita S, Masago K, Katakami N, Yatabe Y. Transformation to SCLC after Treatment with the ALK Inhibitor Alectinib. J Thorac Oncol 2016; 11: e67-e72.","DOI":"10.1016\/j.jtho.2015.12.105"},{"key":"ref-1688021","doi-asserted-by":"crossref","unstructured":"Cha YJ, Cho BC, Kim HR, Lee HJ, Shim HS. A Case of ALK-Rearranged Adenocarcinoma with Small Cell Carcino\u00adma-Like Transformation and Resistance to Crizotinib. J Thorac Oncol 2016; 11: e55-e58.","DOI":"10.1016\/j.jtho.2015.12.097"},{"key":"ref-1688022","doi-asserted-by":"crossref","unstructured":"Levacq D, D'Haene N, de Wind R, Remmekink M, Bergh\u00admans T. Histological transformation of ALK rearranged ade\u00adnocarcinoma into small cell lung cancer: A new mechanism of resistance to ALK inhibitors. Lung Cancer 2016; 102: 38-41.","DOI":"10.1016\/j.lungcan.2016.10.012"},{"key":"ref-1688023","doi-asserted-by":"crossref","unstructured":"Zhu YC, Liao XH, Wang WX, et al. Patients harboring ALK rearrangement adenocarcinoma after acquired resistance to crizotinib and transformation to small-cell lung cancer: a case report. Onco Targets Ther 2017; 10: 3187-3192.","DOI":"10.2147\/OTT.S139718"},{"key":"ref-1688024","doi-asserted-by":"crossref","unstructured":"Miyamoto S, Ikushima S, Ono R, et al. Transformation to small-cell lung cancer as a mechanism of acquired resistance to crizotinib and alectinib. Jpn J Clin Oncol 2016; 46: 170-173.","DOI":"10.1093\/jjco\/hyv173"},{"key":"ref-1688025","doi-asserted-by":"crossref","unstructured":"Ren X, Cai X, Li J, et al. Histological transformation of lung adenocarcinoma to small cell lung cancer with mutant C797S conferring acquired resistance to osimertinib. J Int Med Res 2020; 48: 300060520927918.","DOI":"10.1177\/0300060520927918"},{"key":"ref-1688026","doi-asserted-by":"crossref","unstructured":"Zhou YZ, Jin J, Tian PW, Li WM. Application of the Next-Generation Sequencing Technology to Reveal Mecha\u00adnism of Small Cell Lung Cancer Transformation from Adeno\u00adcarcinoma. Chin Med J (Engl) 2018; 131: 1124-1125.","DOI":"10.4103\/0366-6999.230720"},{"key":"ref-1688027","doi-asserted-by":"crossref","unstructured":"Zhang Y, Li XY, Tang Y, et al. Rapid increase of serum neuron spe\u00adcific enolase level and tachyphylaxis of EGFR-tyrosine kinase in\u00adhibitor indicate small cell lung cancer transformation from EGFR positive lung adenocarcinoma? Lung Cancer 2013; 81: 302-305.","DOI":"10.1016\/j.lungcan.2013.04.005"},{"key":"ref-1688028","doi-asserted-by":"crossref","unstructured":"Minari R, Bordi P, Del Re M, et al. Primary resistance to osime\u00adrtinib due to SCLC transformation: Issue of T790M determina\u00adtion on liquid re-biopsy. Lung Cancer 2018; 115: 21-27.","DOI":"10.1016\/j.lungcan.2017.11.011"},{"key":"ref-1688029","doi-asserted-by":"crossref","unstructured":"Ma S, He Z, Fu H, et al. Dynamic changes of acquired T790M mutation and small cell lung cancer transformation in a patient with EGFR-mutant adenocarcinoma after first- and third-gen\u00aderation EGFR-TKIs: a case report. Transl Lung Cancer Res 2020; 9: 139-143.","DOI":"10.21037\/tlcr.2020.01.07"},{"key":"ref-1688030","doi-asserted-by":"crossref","unstructured":"Chu X, Li Y, Zhu Z. A Case of Small Cell Lung Cancer Trans\u00adformation from EGFR-Mutant Lung Adenocarcinoma with Primary Resistance to Gefitinib. J Thorac Oncol 2018; 13: e211-e214.","DOI":"10.1016\/j.jtho.2018.05.022"},{"key":"ref-1688031","doi-asserted-by":"crossref","unstructured":"Liu J, Li X, Peng J. A Novel CAV1-MET Fusion in SCLC Transformation Responds to Crizotinib and Osimertinib Treat\u00adment. J Thorac Oncol 2019; 14: e126-e128.","DOI":"10.1016\/j.jtho.2019.01.025"},{"key":"ref-1688032","doi-asserted-by":"crossref","unstructured":"Nishikawa S, Tambo Y, Ninomiya H, et al. A case treated with nivolumab after small cell lung cancer transformation of mu\u00adtant EGFR non-small cell lung cancer. Ann Oncol 2016; 27: 2300-2302.","DOI":"10.1093\/annonc\/mdw431"},{"key":"ref-1688033","doi-asserted-by":"crossref","unstructured":"Lee JK, Lee J, Kim S, et al. Clonal History and Genetic Predic\u00adtors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas. J Clin Oncol 2017; 35: 3065-3074.","DOI":"10.1200\/JCO.2016.71.9096"},{"key":"ref-1688034","doi-asserted-by":"crossref","unstructured":"Lu H, Chen B, Qin J, Xie F, Han N, Huang Z. Transforma\u00adtion to small-cell lung cancer following treatment with icotinib in a patient with lung adenocarcinoma. Oncol Lett 2018; 15: 5799-5802.","DOI":"10.3892\/ol.2018.8040"},{"key":"ref-1688035","doi-asserted-by":"crossref","unstructured":"Fang L, He J, Xia J, et al. Resistance to epithelial growth factor receptor tyrosine kinase inhibitors in a patient with transfor\u00admation from lung adenocarcinoma to small cell lung cancer: A case report. Oncol Lett 2017; 14: 593-598.","DOI":"10.3892\/ol.2017.6229"},{"key":"ref-1688036","doi-asserted-by":"crossref","unstructured":"Fallet V, Ruppert AM, Poulot V, et al. Secondary resistance to erlotinib: acquired T790M mutation and small-cell lung can\u00adcer transformation in the same patient. J Thorac Oncol 2012; 7: 1061-1063.","DOI":"10.1097\/JTO.0b013e31824fea45"},{"key":"ref-1688037","doi-asserted-by":"crossref","unstructured":"Suda K, Murakami I, Sakai K, et al. Small cell lung cancer transformation and T790M mutation: complimentary roles in acquired resistance to kinase inhibitors in lung cancer. Sci Rep 2015; 5: 14447.","DOI":"10.1038\/srep14447"},{"key":"ref-1688038","doi-asserted-by":"crossref","unstructured":"Liu Y. Small cell lung cancer transformation from EGFR-mu\u00adtated lung adenocarcinoma: A case report and literatures re\u00adview. Cancer Biol Ther 2018; 19: 445-449.","DOI":"10.1080\/15384047.2018.1435222"},{"key":"ref-1688039","doi-asserted-by":"crossref","unstructured":"Jiang SY, Zhao J, Wang MZ, et al. Small-Cell Lung Cancer Transformation in Patients With Pulmonary Adenocarcino\u00adma: A Case Report and Review of Literature. Medicine (Balti\u00admore) 2016; 95: e2752.","DOI":"10.1097\/MD.0000000000002752"},{"key":"ref-1688040","doi-asserted-by":"crossref","unstructured":"Al\u00ec G, Bruno R, Giordano M, et al. Small cell lung cancer transformation and the T790M mutation: A case report of two acquired mechanisms of TKI resistance detected in a tumor rebiopsy and plasma sample of EGFR-mutant lung adenocar\u00adcinoma. Oncol Lett 2016; 12: 4009-4012.","DOI":"10.3892\/ol.2016.5193"},{"key":"ref-1688041","doi-asserted-by":"crossref","unstructured":"Yang H, Liu L, Zhou C, et al. The clinicopathologic of pulmo\u00adnary adenocarcinoma transformation to small cell lung cancer. Medicine (Baltimore) 2019; 98: e14893.","DOI":"10.1097\/MD.0000000000014893"},{"key":"ref-1688042","doi-asserted-by":"crossref","unstructured":"Shiroyama T, Nasu S, Tanaka A, et al. Transformation to small cell lung cancer after first-line afatinib treatment. Respir Med Case Rep 2018; 23: 188-190.","DOI":"10.1016\/j.rmcr.2018.02.011"},{"key":"ref-1688043","doi-asserted-by":"crossref","unstructured":"Hwang KE, Jung JW, Oh SJ, et al. Transformation to small cell lung cancer as an acquired resistance mechanism in EGFR-mu\u00adtant lung adenocarcinoma: a case report of complete response to etoposide and cisplatin. Tumori 2015; 101: e96-8.","DOI":"10.5301\/tj.5000276"},{"key":"ref-1688044","doi-asserted-by":"crossref","unstructured":"Watanabe S, Sone T, Matsui T, et al. Transformation to small-cell lung cancer following treatment with EGFR tyrosine ki\u00adnase inhibitors in a patient with lung adenocarcinoma. Lung Cancer 2013; 82: 370-372.","DOI":"10.1016\/j.lungcan.2013.06.003"},{"key":"ref-1688045","doi-asserted-by":"crossref","unstructured":"Ham JS, Kim S, Kim HK, et al. Two Cases of Small Cell Lung Cancer Transformation from EGFR Mutant Adenocarcinoma During AZD9291 Treatment. J Thorac Oncol 2016; 11: e1-4.","DOI":"10.1016\/j.jtho.2015.09.013"},{"key":"ref-1688046","doi-asserted-by":"crossref","unstructured":"Gu Y, Zhu X, Cao B, et al. Transformation to small cell lung cancer and activation of KRAS during long-term erlotin\u00adib maintenance in a patient with non-small cell lung cancer: A case report. Oncol Lett 2019; 17: 5219-5223.","DOI":"10.3892\/ol.2019.10196"},{"key":"ref-1688047","doi-asserted-by":"crossref","unstructured":"Xie T, Li Y, Ying J, et al. Whole exome sequencing (WES) analysis of transformed small cell lung cancer (SCLC) from lung adenocarcinoma (LUAD). Transl Lung Cancer Res 2020; 9: 2428-2439.","DOI":"10.21037\/tlcr-20-1278"},{"key":"ref-1688048","doi-asserted-by":"crossref","unstructured":"Si X, You Y, Zhang X, Wang H, Wang M, Zang L. Histologic transformation of lung cancer during pembrolizumab therapy: A case report. Thorac Cancer 2020; 11: 793-796.","DOI":"10.1111\/1759-7714.13312"},{"key":"ref-1688049","doi-asserted-by":"crossref","unstructured":"Miura N, Matsubara T, Takamori S, et al. Histological conver\u00adsion from adenocarcinoma to small cell carcinoma of the lung after treatment with an immune checkpoint inhibitor: a case report. Oxf Med Case Reports 2020; 2020: omaa026.","DOI":"10.1093\/omcr\/omaa026"},{"key":"ref-1688050","doi-asserted-by":"crossref","unstructured":"Balla A, Khan F, Hampel KJ, Aisner DL, Sidiropoulos N. Small-cell transformation of ALK-rearranged non-small-cell adenocarcinoma of the lung. Cold Spring Harb Mol Case Stud 2018; 4: a002394.","DOI":"10.1101\/mcs.a002394"},{"key":"ref-1688051","doi-asserted-by":"crossref","unstructured":"Ou SI, Lee TK, Young L, et al. Dual occurrence of ALK G1202R solvent front mutation and small cell lung cancer transformation as resistance mechanisms to second generation ALK inhibitors without prior exposure to crizotinib. Pitfall of solely relying on liquid re-biopsy? Lung Cancer 2017; 106: 110-114.","DOI":"10.1016\/j.lungcan.2017.02.005"},{"key":"ref-1688052","doi-asserted-by":"crossref","unstructured":"Xia G, Huang J, Ni J, et al. Transformation of ALK-positive NSCLC to SCLC after alectinib resistance and response to combined atezolizumab: a case report. Transl Lung Cancer Res 2023; 12: 637-646.","DOI":"10.21037\/tlcr-23-154"},{"key":"ref-1688053","doi-asserted-by":"crossref","unstructured":"Fang G, Liu W, Shang Y, et al. Characterization of non-small cell lung cancer transforming to small cell lung cancer and its response to EGFR-TKI: a case report. Ann Transl Med 2022; 10: 115.","DOI":"10.21037\/atm-21-6991"},{"key":"ref-1688054","doi-asserted-by":"crossref","unstructured":"Yu L, Bazhenova L, Gold K, et al. Clinicopathologic and mo\u00adlecular characteristics of EGFR-mutant lung adenocarcinomas that transform to small cell lung cancer after TKI therapy. Transl Lung Cancer Res 2022; 11: 452-461.","DOI":"10.21037\/tlcr-21-665"},{"key":"ref-1688055","doi-asserted-by":"crossref","unstructured":"Vendrell JA, Quantin X, Serre I, Solassol J. Combination of tissue and liquid biopsy molecular profiling to detect transfor\u00admation to small cell lung carcinoma during osimertinib treat\u00adment. Ther Adv Med Oncol 2020; 12: 1758835920974192.","DOI":"10.1177\/1758835920974192"},{"key":"ref-1688056","doi-asserted-by":"crossref","unstructured":"Hui M, Uppin SG, Stalin BJ, Sadashivudu G. Histological transformation of adenocarcinoma to small cell carcinoma lung as a rare mechanism of resistance to epidermal growth factor receptor-tyrosine kinase inhibitors: Report of a case with re\u00adview of literature. Lung India 2018; 35: 160-163.","DOI":"10.4103\/lungindia.lungindia_347_17"},{"key":"ref-1688057","doi-asserted-by":"crossref","unstructured":"Jin CB, Yang L. Histological transformation of non-small cell lung cancer: Clinical analysis of nine cases. World J Clin Cases 2021; 9: 4617-4626.","DOI":"10.12998\/wjcc.v9.i18.4617"},{"key":"ref-1688058","doi-asserted-by":"crossref","unstructured":"Tokaca N, Wotherspoon A, Nicholson AG, Fotiadis N Thomp\u00adson L, Popat S. Lack of response to nivolumab in a patient with EGFR-mutant non-small cell lung cancer adenocarcinoma sub-type transformed to small cell lung cancer. Lung Cancer 2017; 111: 65-68.","DOI":"10.1016\/j.lungcan.2017.07.012"},{"key":"ref-1688059","doi-asserted-by":"crossref","unstructured":"Zhou Y, Bai H, Xia J, Xu WY, Cheng L, Xiong L. Novel ETV1 mutation in small cell lung cancer transformation resistant to EGFR tyrosine kinase inhibitors. Ann Transl Med 2021; 9: 1150.","DOI":"10.21037\/atm-21-2625"},{"key":"ref-1688060","doi-asserted-by":"crossref","unstructured":"Pignataro D, Bertaglia V, Bironzo P, et al. Oligoprogres\u00adsive Disease With SCLC Transformation in EGFR-Mutated NSCLC: How Biology Knowledge Can Change the Game Rules. J Thorac Oncol 2020; 15: e170-e172.","DOI":"10.1016\/j.jtho.2020.06.020"},{"key":"ref-1688061","doi-asserted-by":"crossref","unstructured":"Tang K, Jiang N, Kuang Y, et al. Overcoming T790M mutant small cell lung cancer with the third-generation EGFR-TKI osimertinib. Thorac Cancer 2019; 10: 359-364.","DOI":"10.1111\/1759-7714.12927"},{"key":"ref-1688062","doi-asserted-by":"crossref","unstructured":"Wang X, Liang J, Li L, Pan Z, Wang L. Reuse of osimertinib after small cell lung cancer transformation in lung adenocarci\u00adnoma with de-novo epidermal growth factor receptor T790M mutation: case report. Anticancer Drugs 2023; 34: 306-310.","DOI":"10.1097\/CAD.0000000000001403"},{"key":"ref-1688063","doi-asserted-by":"crossref","unstructured":"Wahab A, Kesari K, Chaudhary S, et al. Sequential occurrence of small cell and non-small lung cancer in a male patient: Is it a transformation? Cancer Biol Ther 2017; 18: 940-943.","DOI":"10.1080\/15384047.2017.1394546"},{"key":"ref-1688064","doi-asserted-by":"crossref","unstructured":"Hong E, Chen XE, Mao J, et al. Sequential occurrence of T790M mutation and small cell lung cancer transformation in EGFR-positive lung adenocarcinoma: A case report. World J Clin Cases 2022; 10: 2836-2843.","DOI":"10.12998\/wjcc.v10.i9.2836"},{"key":"ref-1688065","doi-asserted-by":"crossref","unstructured":"Zhang C, Lin L, Guo X, Chen P. Significance of genetic se\u00adquencing in patients with lung adenocarcinoma with transfor\u00admation to small cell lung cancer: a case report and systematic review. Transl Cancer Res 2020; 9: 3725-3733.","DOI":"10.21037\/tcr-19-2291"},{"key":"ref-1688066","doi-asserted-by":"crossref","unstructured":"Taniguchi Y, Horiuchi H, Morikawa T, Usui K. Small-Cell Carcinoma Transformation of Pulmonary Adenocarcinoma af\u00adter Osimertinib Treatment: A Case Report. Case Rep Oncol 2018; 11: 323-329.","DOI":"10.1159\/000489603"},{"key":"ref-1688067","doi-asserted-by":"crossref","unstructured":"Otoshi R, Sekine A, Okudela K, et al. Small-cell lung carci\u00adnoma transformation of lung adenocarcinoma diagnosed by pericardial effusion: A case report. Mol Clin Oncol 2020; 13: 129-132.","DOI":"10.3892\/mco.2020.2059"},{"key":"ref-1688068","doi-asserted-by":"crossref","unstructured":"El Hussein S, Khader SN. Transformation of lung adenocarcino\u00adma to small cell lung carcinoma in the setting of tyrosine kinase inhibitor therapy: Cytological approach of a clinically challeng\u00ading phenomenon. Diagn Cytopathol 2019; 47: 845-850.","DOI":"10.1002\/dc.24193"},{"key":"ref-1688069","doi-asserted-by":"crossref","unstructured":"Lai L, Meng W, Wei J, et al. Transformation of NSCLC to SCLC after 1st- and 3rd-generation EGFR-TKI resistance and response to EP regimen and erlotinib: 2 CARE-compliant case reports. Medicine (Baltimore) 2021; 100: e25046.","DOI":"10.1097\/MD.0000000000025046"},{"key":"ref-1688070","doi-asserted-by":"crossref","unstructured":"Hao L, Chen H, Wang L, et al. Transformation or tumor heter\u00adogeneity: Mutations in EGFR, SOX2, TP53, and RB1 persist in the histological rapid conversion from lung adenocarcino\u00adma to small-cell lung cancer. Thorac Cancer 2023; 14: 1036- 1041.","DOI":"10.1111\/1759-7714.14832"},{"key":"ref-1688071","doi-asserted-by":"crossref","unstructured":"Popat S, Wotherspoon A, Nutting CM, Gonzalez D, Nicholson AG, O'Brien M. Transformation to \u201chigh grade\u201d neuroendo\u00adcrine carcinoma as an acquired drug resistance mechanism in EGFR-mutant lung adenocarcinoma. Lung Cancer 2013; 80: 1-4.","DOI":"10.1016\/j.lungcan.2012.12.019"},{"key":"ref-1688072","doi-asserted-by":"crossref","unstructured":"Xie Z, Gu Y, Lin X, et al. Unexpected favorable outcome to etoposide and cisplatin in a small cell lung cancer transformed patient: a case report. Cancer Biol Ther 2019; 20: 1172-1175.","DOI":"10.1080\/15384047.2019.1617561"},{"key":"ref-1688073","doi-asserted-by":"crossref","unstructured":"Simarro J, P\u00e9rez-Sim\u00f3 G, Manche\u00f1o N, et al. Utility of Next-Generation Sequencing in the Reconstruction of Clonal Architecture in a Patient with an EGFR Mutated Advanced Non-Small Cell Lung Cancer: A Case Report. Diagnostics (Ba\u00adsel) 2022; 12: 1266.","DOI":"10.3390\/diagnostics12051266"},{"key":"ref-1688074","doi-asserted-by":"crossref","unstructured":"Liu H, Chen LH, Zhang ZH, et al. Histomorphological trans\u00adformation from non-small cell lung carcinoma to small cell lung carcinoma after targeted therapy or immunotherapy: A report of two cases. Front Oncol 2022; 12: 1022705.","DOI":"10.3389\/fonc.2022.1022705"},{"key":"ref-1688075","doi-asserted-by":"crossref","unstructured":"Gazeu A, Aubert M, Pissaloux D, et al. Small-Cell Lung Can\u00adcer Transformation as a Mechanism of Resistance to Pralsetin\u00adib in RET-Rearranged Lung Adenocarcinoma: A Case Report. Clin Lung Cancer 2023; 24: 72-75.","DOI":"10.1016\/j.cllc.2022.10.005"},{"key":"ref-1688076","doi-asserted-by":"crossref","unstructured":"Zhai X, Liu J, Liang Z, et al. Case Report: Re-Sensitization to Gefitinib in Lung Adenocarcinoma Harboring EGFR Muta\u00adtion and High PD-L1 Expression After Immunotherapy Re\u00adsistance, Which Finally Transform Into Small Cell Carcinoma. Front Oncol 2021; 11: 661034.","DOI":"10.3389\/fonc.2021.661034"},{"key":"ref-1688077","doi-asserted-by":"crossref","unstructured":"Leonetti A, Minari R, Mazzaschi G, Adrieansen D Song JY, Berns A. Small Cell Lung Cancer Transformation as a Resist\u00adance Mechanism to Osimertinib in Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: Case Report and Literature Review. Front Oncol 2021; 11: 642190.","DOI":"10.3389\/fonc.2021.642190"},{"key":"ref-1688078","doi-asserted-by":"crossref","unstructured":"Marcoux N, Gettinger SN, O'Kane G, et al. EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes. J Clin Oncol 2019; 37: 278-285.","DOI":"10.1200\/JCO.18.01585"},{"key":"ref-1688079","doi-asserted-by":"crossref","unstructured":"Offin M, Chan JM, Tenet M, et al. Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Out\u00adcomes. J Thorac Oncol 2019; 14: 1784-1793.","DOI":"10.1016\/j.jtho.2019.06.002"},{"key":"ref-1688080","doi-asserted-by":"crossref","unstructured":"Sutherland KD, Proost N, Brouns I, et al. Cell of origin of small cell lung cancer: inactivation of Trp53 and Rb1 in dis\u00adtinct cell types of adult mouse lung. Cancer Cell 2011; 19: 754-764.","DOI":"10.1016\/j.ccr.2011.04.019"},{"key":"ref-1688081","doi-asserted-by":"crossref","unstructured":"Sutherland KD, Song JY, Kwon MC, Proost N, Zevenhoven J, Berns A. Multiple cells-of-origin of mutant K-Ras-induced mouse lung adenocarcinoma. Proc Natl Acad Sci U S A. 2014; 111: 4952-4957.","DOI":"10.1073\/pnas.1319963111"},{"key":"ref-1688082","doi-asserted-by":"crossref","unstructured":"Mainardi S, Mijimolle N, Francoz S, Vicente-Due\u00f1as C, S\u00e1nchez-Garc\u00eda I, Barbacid M. Identification of cancer initiat\u00ading cells in K-Ras driven lung adenocarcinoma. Proc Natl Acad Sci U S A 2014; 111: 255-260.","DOI":"10.1073\/pnas.1320383110"}],"container-title":["Polish Journal of Pathology"],"original-title":[],"link":[{"URL":"https:\/\/www.polishjournalofpathology.com\/pdf-208069-136515","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.polishjournalofpathology.com\/pdf-208069-136515","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T11:12:34Z","timestamp":1782213154000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.polishjournalofpathology.com\/Clinicopathological-and-molecular-features-of-non-small-cell-lung-cancer-that-transform,208069,0,2.html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,22]]},"references-count":86,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025]]}},"alternative-id":["208069"],"URL":"https:\/\/doi.org\/10.5114\/pjp.2025.153971","relation":{},"ISSN":["1233-9687","2084-9869"],"issn-type":[{"value":"1233-9687","type":"print"},{"value":"2084-9869","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,22]]}}}